Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?

Key Takeaways Lilly has filed orforglipron for obesity and is advancing retatrutide in late-stage studiesOrforglipron filings span the U.S. and EU, with a U.S. obesity launch expected in Q2 2026.Retatrutide showed strong weight loss and pain relief in patients with obesity and knee osteoarthritis painEli Lilly and Company (LLY) is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, supported by the strong success of its GLP-1–based therapies — Mounjaro for type II di ...